Oseltamivir acid

Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses[1][2].

Product Specifications

CAS Number

[187227-45-8]

Product Name Alternative

GS 4071; Ro 64-0802; Oseltamivir carboxylate

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite; Influenza Virus

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Oseltamivir-acid.html

Purity

99.80

Solubility

DMSO : ≥ 230 mg/mL|H2O : 250 mg/mL (ultrasonic)

Smiles

O=C(O)C1=C[C@H]([C@@H]([C@H](C1)N)NC(C)=O)OC(CC)CC

Molecular Formula

C14H24N2O4

Molecular Weight

284.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Li W, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother. 1998 Mar;42 (3) :647-53.|[2]Ghosh GC, et al. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect. 2010 Jan;118 (1) :103-7.|[3]Ferraris O, et al. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 2005 Oct;68 (1) :43-8.|[4]Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Antimicrob Agents Chemother. 2001 Dec;45 (12) :3403-8.|[5]Yen HL, et al. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis. 2005 Aug 15;192 (4) :665-72.|[6]Hoffmann G, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53 (11) :4753-61.